These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 8867293

  • 1. Management of ventricular fibrillation with transvenous defibrillators without baseline electrophysiologic testing or antiarrhythmic drugs.
    Dolack GL, Poole JE, Kudenchuk PJ, Raitt MH, Gleva MJ, Anderson J, Troutman C, Bardy GH.
    J Cardiovasc Electrophysiol; 1996 Mar; 7(3):197-202. PubMed ID: 8867293
    [Abstract] [Full Text] [Related]

  • 2. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA, Banchs JE, Depalma S, Young SK, Penny-Peterson ED, Samii SM, Wolbrette DL, Naccarelli GV, Gonzalez MD.
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [Abstract] [Full Text] [Related]

  • 3. Implantable transvenous cardioverter-defibrillators.
    Bardy GH, Hofer B, Johnson G, Kudenchuk PJ, Poole JE, Dolack GL, Gleva M, Mitchell R, Kelso D.
    Circulation; 1993 Apr; 87(4):1152-68. PubMed ID: 8462144
    [Abstract] [Full Text] [Related]

  • 4. Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy.
    Elliott PM, Sharma S, Varnava A, Poloniecki J, Rowland E, McKenna WJ.
    J Am Coll Cardiol; 1999 May; 33(6):1596-601. PubMed ID: 10334430
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Efficacy of automatic multimodal device therapy for ventricular tachyarrhythmias as delivered by a new implantable pacing cardioverter-defibrillator. Results of a European multicenter study of 102 implants.
    Fromer M, Brachmann J, Block M, Siebels J, Hoffmann E, Almendral J, Ohm OJ, den Dulk K, Coumel P, Camm AJ.
    Circulation; 1992 Aug; 86(2):363-74. PubMed ID: 1638705
    [Abstract] [Full Text] [Related]

  • 7. Follow-up of patients with unexplained syncope and inducible ventricular tachyarrhythmias: analysis of the AVID registry and an AVID substudy. Antiarrhythmics Versus Implantable Defibrillators.
    Steinberg JS, Beckman K, Greene HL, Marinchak R, Klein RC, Greer SG, Ehlert F, Foster P, Menchavez E, Raitt M, Wathen MS, Morris M, Hallstrom A.
    J Cardiovasc Electrophysiol; 2001 Sep; 12(9):996-1001. PubMed ID: 11573709
    [Abstract] [Full Text] [Related]

  • 8. Ventricular tachycardia/fibrillation early after defibrillator implantation in patients with hypertrophic cardiomyopathy is explained by a high-risk subgroup of patients.
    Alsheikh-Ali AA, Link MS, Semsarian C, Shen WK, Estes NA, Maron MS, Haas TS, Formisano F, Boriani G, Spirito P, Maron BJ.
    Heart Rhythm; 2013 Feb; 10(2):214-8. PubMed ID: 23041573
    [Abstract] [Full Text] [Related]

  • 9. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
    Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators.
    N Engl J Med; 1997 Nov 27; 337(22):1576-83. PubMed ID: 9411221
    [Abstract] [Full Text] [Related]

  • 10. Appropriate ICD therapy in patients with idiopathic dilated cardiomyopathy: long term follow-up.
    Karaoguz R, Maydanozcu S, Altun T, Güldal M, Akyürek O, Erol C.
    Int Heart J; 2006 Sep 27; 47(5):763-73. PubMed ID: 17106147
    [Abstract] [Full Text] [Related]

  • 11. Management of patients with life-threatening sustained ventricular tachyarrhythmias--the role of guided antiarrhythmic drug therapy.
    Steinbeck G, Greene HL.
    Prog Cardiovasc Dis; 1996 Sep 27; 38(6):419-28. PubMed ID: 8638023
    [Abstract] [Full Text] [Related]

  • 12. Comparison of arrhythmia recurrence in patients presenting with ventricular fibrillation versus ventricular tachycardia in the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial.
    Raitt MH, Klein RC, Wyse DG, Wilkoff BL, Beckman K, Epstein AE, Coromilas J, Friedman PL, Martins J, Ledingham RB, Greene HL, Antiarrhythmics Versus Implantable Defibrillators Investigators.
    Am J Cardiol; 2003 Apr 01; 91(7):812-6. PubMed ID: 12667566
    [Abstract] [Full Text] [Related]

  • 13. Idiopathic ventricular fibrillation: clinical, electrophysiologic characteristics and long-term outcomes.
    Tsai CF, Chen SA, Tai CT, Chiang CE, Ding YA, Chang MS.
    Int J Cardiol; 1998 Mar 13; 64(1):47-55. PubMed ID: 9579816
    [Abstract] [Full Text] [Related]

  • 14. Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.
    AbdelWahab A, Sapp J.
    Curr Cardiol Rep; 2017 Sep 13; 19(11):105. PubMed ID: 28900864
    [Abstract] [Full Text] [Related]

  • 15. The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
    Zarraga IG, Dougherty CM, MacMurdy KS, Raitt MH.
    Circ Arrhythm Electrophysiol; 2012 Aug 01; 5(4):739-47. PubMed ID: 22773022
    [Abstract] [Full Text] [Related]

  • 16. Ventricular Tachyarrhythmias in Patients With Hypertrophic Cardiomyopathy and Defibrillators: Triggers, Treatment, and Implications.
    Link MS, Bockstall K, Weinstock J, Alsheikh-Ali AA, Semsarian C, Estes NAM, Spirito P, Haas TS, Rowin EJ, Maron MS, Maron BJ.
    J Cardiovasc Electrophysiol; 2017 May 01; 28(5):531-537. PubMed ID: 28240435
    [Abstract] [Full Text] [Related]

  • 17. Results of delivered therapy for VT or VF in patients with third-generation implantable cardioverter defibrillators.
    Rabinovich R, Muratore C, Iglesias R, Gonzalez M, Serafrica M, Sosa Liprandi A.
    Pacing Clin Electrophysiol; 1995 Jan 01; 18(1 Pt 2):133-6. PubMed ID: 7724386
    [Abstract] [Full Text] [Related]

  • 18. Clinical significance of the electrophysiologic study (EPS)-guided therapy for the secondary prevention of ventricular tachycardia.
    Yuge M, Niwano S, Moriguchi M, Sasaki T, Hirasawa S, Imaki R, Sato D, Izumi T.
    Circ J; 2006 Mar 01; 70(3):268-72. PubMed ID: 16501291
    [Abstract] [Full Text] [Related]

  • 19. Antiarrhythmic Drugs for Nonshockable-Turned-Shockable Out-of-Hospital Cardiac Arrest: The ALPS Study (Amiodarone, Lidocaine, or Placebo).
    Kudenchuk PJ, Leroux BG, Daya M, Rea T, Vaillancourt C, Morrison LJ, Callaway CW, Christenson J, Ornato JP, Dunford JV, Wittwer L, Weisfeldt ML, Aufderheide TP, Vilke GM, Idris AH, Stiell IG, Colella MR, Kayea T, Egan D, Desvigne-Nickens P, Gray P, Gray R, Straight R, Dorian P, Resuscitation Outcomes Consortium Investigators.
    Circulation; 2017 Nov 28; 136(22):2119-2131. PubMed ID: 28904070
    [Abstract] [Full Text] [Related]

  • 20. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
    Giorgberidze I, Saksena S, Krol RB, Munsif AN, Kolettis T, Mathew P, Varanasi S, Prakash A, Delfaut P, Lewis CB.
    Am J Cardiol; 1997 Sep 11; 80(5B):3F-9F. PubMed ID: 9291444
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.